NEW YORK (GenomeWeb) – Abbott today reported that its diagnostics sales jumped 5 percent year over year in the second quarter, but molecular diagnostics was a drag on the business, falling 2 percent.

The medical products giant reported total revenues of $5.55 billion for the quarter ended June 30, up 2 percent from $5.45 billion for Q2 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A company hopes to capture the genetic diversity in India to power tailored therapeutics, BBC News reports.

Researchers tie variants in seven genes to insomnia risk, Live Science reports.

The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.

In PLOS this week: locus near OAS1 linked to Sjogren's syndrome, rotavirus reassortment events uncovered by sequencing, and more.